Clinical Trial

SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma

Name: SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma — clinical trial record (NCT07700667)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with Esophageal Squamous Cell Carcinoma. The study is divided into three parts: the safety run-in phase, randomized enrollment phase and cohort expansion phase.

Trial Details

NCT Number	NCT07700667
Lead Sponsor	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions	Esophageal Squamous Cell Carcinoma
Enrollment	120 participants
Start Date	2026-07-30
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-14